GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

AnaptysBio’s trial saw 69% of its rheumatoid arthritis patients treated with rosnilimab achieve low disease activity by week ...

Moleculin Biotech has received approval in Ukraine to begin enrolment in its trial of annamycin with cytarabine for acute ...

Patients who received a single injection of Lumevoq displayed sustained clinical recovery in a rare condition that can lead ...

Rallybio has dosed the first subject in a trial of a potential treament for foetal and neonatal alloimmune thrombocytopaenia (FNAIT).